Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006416
Abstract: Key Points • In CM-TMA, variants in specific genes/regions are associated with high risk of relapse after eculizumab is discontinued.• In CM-TMA, eculizumab discontinuation is appropriate in patients with a low risk of relapse. read more here.
Keywords: effect relapse; complement; relapse; complement gene ... See more keywords